Novo Nordisk , whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in ...
Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...
Novo Nordisk’s stock declined 12% in the past month. Wegovy's sales growth stays under pressure. Read why I'm neutral on NVO ...
Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could ...
Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...
Danish drug maker Novo Nordisk produces a GLP-1 Semaglutide, sold under brand names Ozempic and Rybelsus in Type 2 diabetes and Wegovy in obesity, which has been labelled a “weight-loss” wonder ...
The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.
The CEO of Novo Nordisk wouldn’t commit to lowering the prices of Ozempic and Wegovy during a Senate hearing Tuesday, despite ...
We recently published a list of Renaissance Technologies Portfolio: 10 Best Stocks To Buy. In this article, we are going to ...
Concerns are rising as Novo Nordisk's $16.5 billion bid to acquire Catalent faces scrutiny from the FTC. Critics argue the ...